Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3,Prospective, Randomized, Double-masked, Placebo-controlled, Parallel Study to Evaluate the Efficacy, PK and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associatedwith Cataract Surgery

NCT06429306 is registered in ClinicalTrials.gov with Ocumension Therapeutics (Shanghai) Co., Ltd as lead sponsor.

NCT NCT06429306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06429306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3,Prospective, Randomized, Double-masked, Placebo-controlled, Parallel Study to Evaluate the Efficacy, PK and Safety of 9% Dexamethasone Intraocular Injection for the Treatment of Inflammation Associatedwith Cataract Surgery
Lead sponsor
Ocumension Therapeutics (Shanghai) Co., Ltd
Phase
Phase 3
Overall status
Completed
Start date
August 22, 2022
Completion date
April 9, 2024
Enrollment
285 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cataract, inflammation